Shantel
Key Takeaways:
- Phantom Neuro, a pioneering neurotech startup, has announced the successful demonstration of their technology in a porcine model, marking a significant preclinical milestone.
- The company is developing a minimally invasive muscle-machine interface to enable lifelike control of robotic prosthetic limbs and exoskeletons.
- Phantom Neuro has appointed a new Chief Technology Officer (CTO), Mike Faltys, and welcomed three distinguished advisors to their board.
- The startup is now focused on advancing towards human trials, aiming to forge partnerships that will accelerate their progress.
Phantom Neuro, a groundbreaking neurotech startup, has achieved a major breakthrough by successfully demonstrating their technology in a porcine model. The company is dedicated to developing the world’s first minimally invasive muscle-machine interface, a revolutionary advancement that enables lifelike control of robotic prosthetic limbs and exoskeletons.
Preclinical Demonstration Validates Phantom Neuro’s Technology
The successful demonstration of their technology in just under one year showcases Phantom Neuro’s rapid progress and commitment to innovation. Dr. Connor Glass, founder and CEO of Phantom Neuro, expressed his excitement, stating, “We went from concept to fully demonstrated system in just under one year, which bodes well for our continued trajectory towards human implementation.”
The preclinical demonstration serves as a crucial validation of Phantom Neuro’s approach and sets the stage for further development and refinement as they move towards human trials. The company’s technology offers immense potential to enhance the lives of amputees and individuals with limb deficits by enabling lifelike control of robotic prosthetic limbs and exoskeletons.
Expansion of Leadership Team and Advisory Board
In conjunction with this milestone, Phantom Neuro has expanded its leadership team with the appointment of Mike Faltys as the new Chief Technology Officer (CTO). Faltys brings a wealth of experience to the role, having previously served as the Vice President of Implantable Systems at Presidio Medical and as the CTO of bioelectronic medicine company SetPoint Medical. His expertise will play a vital role in driving Phantom Neuro’s technological advancements.
Additionally, Phantom Neuro has welcomed three distinguished advisors to their advisory board. Dr. Thomas Oxley, co-founder, and CEO of Synchron, Dr. Brian Otis, co-founder, and former CTO of Verily Life Sciences, and Joshua Duyan, former Chief Strategy Officer of CTRL-labs (acquired by Meta), have joined the team. These industry-leading advisors will provide valuable insights and guidance as Phantom Neuro progresses towards human trials and further development.
Aiming for Human Trials and Strategic Partnerships
With the successful preclinical demonstration and the bolstering of their team through the new CTO appointment and advisory board additions, Phantom Neuro is poised to advance towards human trials. The company is actively seeking partnerships with organizations that share their vision and can contribute to the realization of their groundbreaking technology.
Phantom Neuro aims to forge collaborations with strategic partners who can provide expertise, resources, and a shared commitment to improving the lives of individuals with limb deficits. By joining forces with like-minded organizations, Phantom Neuro aims to accelerate the development and commercialization of their muscle-machine interface technology.
About Phantom Neuro
Phantom Neuro is a pioneering neurotechnology company that emerged from a lab at the Johns Hopkins University School of Medicine. Their focus is on developing the world’s first minimally invasive muscle-machine interface for the control of prosthetic limbs and robotic exoskeletons. Through their innovative approach, Phantom Neuro aims to revolutionize the field of neurotech by providing individuals with enhanced control over artificial limbs and exoskeletons, ultimately improving their quality of life.
The company’s solution combines minimally invasive implantable sensors and artificial intelligence to offer unparalleled control of orthopedic technologies. By harnessing the power of advanced neural interfaces, Phantom Neuro is pushing the boundaries of what is possible in the realm of limb control and mobility.
